Peptides Explained

Do growth hormone secretagogues increase cancer risk?

This episode breaks down the real science behind IGF-1, cancer biology, and compounds like MK-677, Ipamorelin, Sermorelin, CJC-1295, and Tesamorelin.

We review:

• Human IGF-1 cancer studies
• Acromegaly data
• Tumor signaling pathways
• Observational vs causal evidence
• What current science actually supports

This podcast is for informational purposes only and is not medical advice.

Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use my link, I may earn a commission at no additional cost to you.

Support the show: OfflinePeptides Affiliate Link

Does BPC-157 cause cancer — or is that claim being oversimplified?

In this episode of Peptides Explained, we take a study-review approach to one of the biggest concerns surrounding BPC-157: its potential angiogenic effects and whether that could theoretically contribute to cancer proliferation.

Angiogenesis means new blood vessel formation. It is essential for normal wound healing and tissue repair, but it also plays a role in tumor biology. That overlap has led to concerns that BPC-157 could "feed" cancer growth.

But what do the studies actually show?

In this episode, we review key papers on BPC-157, including:

• Hsieh et al., 2017 — VEGFR2 activation and angiogenesis • Radeljak, Seiwerth, and Sikiric, 2004 — melanoma cell-line data • Kang et al., 2018 — cancer cachexia context • Masnec et al., 2015 — corneal injury and neovascularization

We break down the difference between physiologic repair signaling and pathologic tumor angiogenesis, and explain why the current evidence does not support the simple claim that BPC-157 causes cancer proliferation.

That said, the lack of strong human oncology safety data means caution is still appropriate, especially for anyone with active cancer, prior cancer, unexplained symptoms, or elevated cancer risk.

This episode is designed as a literature review for clinicians, physicians, and scientifically curious listeners who want a balanced, evidence-based explanation.

Disclaimer: This content is for informational and educational purposes only and is not medical advice. Always consult a licensed healthcare professional before considering any therapy.

Affiliate disclosure: Peptides Explained is an affiliate partner with OfflinePeptides.com. If you use my link, I may earn a commission at no additional cost to you. https://offlinepeptides.com/ref/JohnGarrett/

#BPC157 #PeptidesExplained #CancerRisk #Angiogenesis #PeptideScience #VEGF #TissueRepair #MedicalEducation #PhysicianReview #Peptides

Tesamorelin is one of the few peptides with FDA approval—but its effects on visceral fat and growth hormone signaling have made it a major topic in metabolic health and body composition circles.

In this episode of Peptides Explained, we break down:

• What tesamorelin actually is • How growth hormone releasing hormone works • Why visceral fat matters metabolically • Clinical trial data and FDA-approved use • Anecdotal outcomes in real-world settings • Risks, limitations, and off-label discussion

We also explain why tesamorelin is different from traditional fat loss medications and why many users report changes in abdominal fat distribution rather than dramatic scale weight loss.

This podcast is for informational purposes only and is not medical advice.

Peptides Explained is an affiliate partner with Offline Peptides. If you use my link, I may earn a commission at no additional cost to you.

In this special update episode, I'm announcing a new affiliate partnership between Peptides Explained and Offline Peptides.

The mission of this podcast remains unchanged: providing clear, responsible, science-based education around peptides, metabolic health, recovery, and emerging therapeutic research.

If you choose to support the show through my affiliate link, I may earn a commission at no additional cost to you.

Affiliate Link: https://offlinepeptides.com/ref/JohnGarrett/

Disclosure: This podcast is for informational and educational purposes only and is not medical advice. Always consult a licensed healthcare professional before considering any therapy or intervention.

Retatrutide may represent the next evolution in metabolic medicine.

In this deep-dive episode of Peptides Explained, we break down the science behind the investigational "triple agonist" peptide that's generating major attention in obesity and metabolic research.

Topics covered: • GLP-1 + GIP + glucagon receptor activation • How retatrutide differs from semaglutide and tirzepatide • Phase 2 clinical trial results • Fat loss vs lean mass loss • Liver fat reduction data • The emerging discussion around obesity-related cancer risk • What may happen after discontinuation • Known side effects and unanswered questions

This episode goes beyond headlines and social media hype to explain the actual biology and human data behind retatrutide.

Peptides Explained is focused on evidence, mechanism, and clarity.

This podcast is for educational purposes only and is not medical advice.

Using the minimal effective dose of GLP-1 medications may be the key to preserving muscle during weight loss. This episode explains how to implement it alongside nutrition and training.

A clinical deep dive into the muscle loss problem on GLP-1 medications. Semaglutide, tirzepatide, and the investigational triple agonist retatrutide all produce remarkable weight loss — but clinical trial data shows that a significant fraction of that loss is lean body mass, not fat. This episode covers the mechanism behind GLP-1-induced muscle wasting, the body composition data from STEP 1 and SURMOUNT trials, who carries the highest risk, and where the next generation of obesity pharmacology — bimagrumab combinations, pemvidutide, and retatrutide's glucagon receptor pathway — is trying to solve the problem. For clinicians, patients, and anyone paying attention to where obesity medicine is actually going.

This podcast is for informational purposes only and is not medical advice.

Breaking news episode. On April 15, 2026, the FDA formally initiated the reclassification process for BPC-157, TB-500, and other peptides restricted since 2023 — publishing a Federal Register notice and scheduling a July 2026 Pharmacy Compounding Advisory Committee meeting. This episode breaks down the full regulatory timeline, what the Category 1 vs Category 2 framework means, what today's action specifically does, and what patients and clinicians should know right now. Clinical, evidence-grounded, no hype.

A clinical breakdown of grey market peptide safety, including contamination risks, testing standards, and how peptide quality impacts biological effects.

GHK-Cu Explained: The Science Behind the Copper Peptide for Skin, Hair, and Healing